Skip to main content
Top
Published in: Tumor Biology 1/2013

01-02-2013 | Research Article

Apoptin selectively induces the apoptosis of tumor cells by suppressing the transcription of HSP70

Authors: Lijie Yuan, Liqiu Zhang, Xingli Dong, Hengyu Zhao, Shuyan Li, Dong Han, Xinghan Liu

Published in: Tumor Biology | Issue 1/2013

Login to get access

Abstract

Apoptin is a nonstructural viral protein encoded by VP3 gene of chicken anemia virus, which could specially induce apoptosis of tumor cells. However, the mechanism of apoptin-induced apoptosis in tumor cells without any side effects in normal cells has not yet been well characterized. This study aimed to investigate the molecular mechanism underlying the selective antitumor effects of apoptin. HepG2 cells were treated with apoptin or transfected with apoptin expression vector. Heat shock protein 70 (HSP70) expression was examined by Western blot. The binding of apoptin to HSP70 promoter was detected by electrophoretic mobility shift assay, chromatin immunoprecipitation, and luciferase assay. The results showed that apoptin inhibited HSP70 expression in HepG2 cells and apoptin-induced apoptosis of HepG2 cells was dependent on the expression level of HSP70. Furthermore, apoptin promoted HSF1 trimer depolymerization and inhibited HSF1-mediated HSP70 transcription. In addition, apoptin competed with HSF1 to bind heat shock element in HSP70 promoter, leading to reduced HSP70 transcription. Both these mechanisms contribute to the suppression of HSP70 transcription and expression. Our findings provide the first evidence that apoptin induces tumor cell apoptosis by specifically downregulating the expression of HSP70, which helps explain the specific antitumor effects of apoptin.
Literature
1.
go back to reference Backendorf C, Visser AE, Boer AG, et al. Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol. 2008;48:143–69.PubMedCrossRef Backendorf C, Visser AE, Boer AG, et al. Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol. 2008;48:143–69.PubMedCrossRef
2.
go back to reference Tavassoli M, Guelen L, Luxon BA, et al. Apoptin: specific killer of tumor cells. Apoptosis. 2005;10:717–24.PubMedCrossRef Tavassoli M, Guelen L, Luxon BA, et al. Apoptin: specific killer of tumor cells. Apoptosis. 2005;10:717–24.PubMedCrossRef
3.
go back to reference Los M, Panigrahi S, Rashedi I, et al. Apoptin, a tumor-selective killer. Biochim Biophys Acta. 2009;1793:1335–42.PubMedCrossRef Los M, Panigrahi S, Rashedi I, et al. Apoptin, a tumor-selective killer. Biochim Biophys Acta. 2009;1793:1335–42.PubMedCrossRef
4.
go back to reference Pietersen A, Erkeland SJ, Rutjes SA, et al. Continuous apoptin expression in transgenic mice does not interfere with lymphocyte development and proliferation. J Med Mol Biol. 2005;2:321–30. Pietersen A, Erkeland SJ, Rutjes SA, et al. Continuous apoptin expression in transgenic mice does not interfere with lymphocyte development and proliferation. J Med Mol Biol. 2005;2:321–30.
5.
go back to reference Zhang YH, Leliveld SR, Kooistra K, et al. Recombinant apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in a normal-cell-specific fashion. Exp Cell Res. 2003;289:36–46.PubMedCrossRef Zhang YH, Leliveld SR, Kooistra K, et al. Recombinant apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in a normal-cell-specific fashion. Exp Cell Res. 2003;289:36–46.PubMedCrossRef
6.
go back to reference Pavet V, Portal MM, Moulin JC, et al. Towards novel paradigms for cancer therapy. Oncogene. 2011;30:1–20.PubMedCrossRef Pavet V, Portal MM, Moulin JC, et al. Towards novel paradigms for cancer therapy. Oncogene. 2011;30:1–20.PubMedCrossRef
8.
go back to reference Oro C, Jans DA. The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr Drug Targets. 2004;5:179–90.PubMedCrossRef Oro C, Jans DA. The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr Drug Targets. 2004;5:179–90.PubMedCrossRef
9.
go back to reference Heilman DW, Teodoro JG, Green MR. Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J Virol. 2006;80:7535–45.PubMedCrossRef Heilman DW, Teodoro JG, Green MR. Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J Virol. 2006;80:7535–45.PubMedCrossRef
10.
go back to reference Poon IK, Oro C, Dias MM, et al. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 2005;65:7059–64.PubMedCrossRef Poon IK, Oro C, Dias MM, et al. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 2005;65:7059–64.PubMedCrossRef
11.
go back to reference Los M, Panigrahi S, Rashedi I, et al. Apoptin, a tumor-selective killer. Biochim Biophys Acta. 2009;1793:1335–42.PubMedCrossRef Los M, Panigrahi S, Rashedi I, et al. Apoptin, a tumor-selective killer. Biochim Biophys Acta. 2009;1793:1335–42.PubMedCrossRef
12.
go back to reference Maddika S, Panigrahi S, Wiechec E. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin’s anticancer toxicity. Mol Cell Biol. 2009;29:1235–48.PubMedCrossRef Maddika S, Panigrahi S, Wiechec E. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin’s anticancer toxicity. Mol Cell Biol. 2009;29:1235–48.PubMedCrossRef
13.
go back to reference Burek M, Maddika S, Burek CJ, et al. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene. 2005;25:2213–22.CrossRef Burek M, Maddika S, Burek CJ, et al. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene. 2005;25:2213–22.CrossRef
14.
go back to reference Maddika S, Booy EP, Johar D, et al. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci. 2005;118:4485–93.PubMedCrossRef Maddika S, Booy EP, Johar D, et al. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci. 2005;118:4485–93.PubMedCrossRef
15.
go back to reference Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004;116:527–40.PubMedCrossRef Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004;116:527–40.PubMedCrossRef
16.
go back to reference Oorschot AAD, Voskamp P, Seelen MC, et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist apoptin and exerts tumor-preferential cell killing. Cell Death Differ. 2004;11:564–73.CrossRef Oorschot AAD, Voskamp P, Seelen MC, et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist apoptin and exerts tumor-preferential cell killing. Cell Death Differ. 2004;11:564–73.CrossRef
17.
go back to reference Beere HM. Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. Sci STKE. 2001;2001: re1. Beere HM. Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. Sci STKE. 2001;2001: re1.
18.
go back to reference Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene. 2004;23:2907–18.PubMedCrossRef Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene. 2004;23:2907–18.PubMedCrossRef
19.
go back to reference Yang X, Wang J, Zhou Y, et al. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett. 2012;321:137–43.PubMedCrossRef Yang X, Wang J, Zhou Y, et al. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett. 2012;321:137–43.PubMedCrossRef
20.
go back to reference Tao ZH, Liu XH, Zhang YW, et al. Expression of TAT-apoptin fusion protein and its anti-tumor activity. Chin J Biochem Mol Biol. 2006;22:535–41. Tao ZH, Liu XH, Zhang YW, et al. Expression of TAT-apoptin fusion protein and its anti-tumor activity. Chin J Biochem Mol Biol. 2006;22:535–41.
21.
go back to reference Pirkkala L, Nykanen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J. 2001;15:1118–31.PubMedCrossRef Pirkkala L, Nykanen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J. 2001;15:1118–31.PubMedCrossRef
22.
go back to reference Evans CG, Chang L, Gestwicki JE. Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem. 2010;53:4585–602.PubMedCrossRef Evans CG, Chang L, Gestwicki JE. Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem. 2010;53:4585–602.PubMedCrossRef
23.
go back to reference Yenari MA, Liu I, Zheng Z, et al. Antiapoptotic and anti inflammatory mechanisms of heat-shock protein protection. Ann N Y Acad Sci. 2005;1053:74–83.PubMedCrossRef Yenari MA, Liu I, Zheng Z, et al. Antiapoptotic and anti inflammatory mechanisms of heat-shock protein protection. Ann N Y Acad Sci. 2005;1053:74–83.PubMedCrossRef
Metadata
Title
Apoptin selectively induces the apoptosis of tumor cells by suppressing the transcription of HSP70
Authors
Lijie Yuan
Liqiu Zhang
Xingli Dong
Hengyu Zhao
Shuyan Li
Dong Han
Xinghan Liu
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0585-y

Other articles of this Issue 1/2013

Tumor Biology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine